Effectiveness and safety of empagliflozin: final results from the EMPRISE study-Reference-Cited by-同舟云学术

Effectiveness and safety of empagliflozin: final results from the EMPRISE study

Published:2024-03-21 Issue:7 Volume:67 Page:1328-1342
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Htoo Phyo T.^ORCID,Tesfaye Helen^ORCID,Schneeweiss Sebastian^ORCID,Wexler Deborah J.^ORCID,Everett Brendan M.,Glynn Robert J.^ORCID,Schmedt Niklas,Koeneman Lisette,Déruaz-Luyet Anouk,Paik Julie M.^ORCID,Patorno Elisabetta^ORCID

Funder

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00125-024-06126-3.pdf

Reference50 articles.

1. Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S et al (2015) Association of cardiometabolic multimorbidity with mortality. JAMA 314(1):52–60. https://doi.org/10.1001/jama.2015.7008

2. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720

3. Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461. https://doi.org/10.1056/nejmoa2107038

4. Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/nejmoa2022190

5. D’Andrea E, Kesselheim AS, Franklin JM, Jung EH, Hey SP, Patorno E (2020) Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 19(1):154. https://doi.org/10.1186/s12933-020-01133-1